EC Number   |
Application |
Reference |
|---|
   5.4.99.9 | analysis |
high-throughput fluorescence polarization assay for indentification of inhibitors of enzyme and homologues |
679168 |
| 5.4.99.9 | drug development |
blocking the incorporation of the product galactofuranose into polysaccharides essential for pathogen viability or virulence may lead to novel therapeutics |
661926 |
| 5.4.99.9 | drug development |
inhibitors of the enzyme that block the biosynthesis of UDP-galactofuranose can lead to novel chemotherapeutics for treating Aspergillus fumigatus-related diseases |
727390 |
| 5.4.99.9 | drug development |
since the enzyme does not exist in Homo sapiens, the parasite enzyme is a target for drug design |
728761 |
| 5.4.99.9 | drug development |
since the enzyme is not present in mammals, it is a promising target for the design of drugs to treat the Chagas' disease caused by Trypanosoma cruzi in humans |
749138 |
| 5.4.99.9 | drug development |
the enzyme is a cell surface virulence factor in protozoan parasites and absent in humans, it is therefore a good drug target |
747079 |
| 5.4.99.9 | drug development |
the enzyme is a potential drug target involved in the synthesis of the cell wall of this fungal pathogen |
726622 |
| 5.4.99.9 | drug development |
the product galactofuranose is valued as an important target for the development of new antituberculosis drugs |
661294 |
| 5.4.99.9 | drug development |
UDP-galactopyranose mutase (UGM), a key enzyme in the biosynthesis of mycobacterial cell walls, is a potential target for the treatment of tuberculosis |
747540 |
| 5.4.99.9 | drug development |
UGM inhibition may provide an attractive drug target in those eukaryotes where galactofuranose plays a critical role in cellular viability and virulence |
661612 |
